Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Scientists dig into mysterious immune cell deficiency

NCT ID NCT02113930

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at 47 people with a rare condition called idiopathic CD4 lymphocytopenia, where the body has too few CD4 immune cells. Researchers collected blood samples and genetic data to understand what causes the condition and how it affects patients. The goal was to improve diagnosis and identify who might benefit from future treatments like IL-2 therapy.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this research could help doctors better identify and understand idiopathic CD4 lymphocytopenia, potentially guiding future treatments.
What could go wrong
This is an observational study with only 47 participants, so findings may not apply to all patients. It does not test a new treatment directly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

47 people

The number who actually took part.

Started

Sep 2013

Finished

Sep 2017

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

200 patients will be included : 100 for which the diagnosis of ICL will be defined on a basis in international classification criteria.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Idiopathic CD4 lymphocytopenia defined as absolute CD4+ T-lymphocyte count \< 300/mm3 or \< 20% of total T cells on more than one cell count; no evidence of infection with HIV-1/2 or human T-cell lymphotropic 1/2 (HTLV-1/2); and lack of a defined immune-deficiency disease or therapy for lymphocytopenia. * Male and female patients can be included * Children and adults can be included * Hospitalized or outpatient Exclusion Criteria: * CD4+ lymphocytopenia due to another condition (HIV infection, sarcoidosis, malignant lymphoma). * Ongoing treatment possibly responsible for CD4 lymphocytopenia. * CD4+ lymphocytopenia related to primary immune deficiency * Absence of consent, of inability to obtain informed consent from the patients or the right holders. * Absence of affiliation to a social security regimen of the patient or the right holder.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Idiopathic CD4+ lymphocytopenia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Cochin Hospital

    Paris, 75014, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.